Aubagio, whose active ingredient is teriflunomide, carries significant risks during pregnancy that must be carefully considered. The medication is known to potentially harm an unborn baby and cause birth defects. Because of this, women are required to have a pregnancy test before starting Aubagio, and they must use effective contraception during treatment and for up to two years after stopping the medication. If a woman becomes pregnant while taking Aubagio, it is critical to inform a healthcare provider immediately to manage the situation appropriately.
The risks are not limited to women; men taking Aubagio also need to be cautious. Teriflunomide can cause birth defects if the father is using it when his partner becomes pregnant. Men are advised to use condoms during sexual intercourse while on the medication and should consult their doctor about stopping treatment if they plan to father a child.
The reason Aubagio poses such risks during pregnancy is related to its mechanism of action and long half-life in the body. Teriflunomide inhibits rapidly dividing cells, which can interfere with fetal development. Its long half-life means it stays in the body for an extended period, which is why contraception is recommended for two years after discontinuation to ensure the drug is sufficiently cleared.
In addition to the risk of birth defects, Aubagio can cause other serious side effects that may complicate pregnancy or general health. These include potential liver problems, which can manifest as pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, unusual tiredness, or yellowing of the eyes or skin. Such symptoms require immediate medical attention.
Aubagio can also lower white blood cell counts, increasing the risk of infections, and reduce platelet counts, which are necessary for blood clotting. These effects can pose additional risks during pregnancy, when the immune system and blood clotting mechanisms are already under strain.
Because of these risks, healthcare providers closely monitor patients on Aubagio with regular blood and urine tests to detect any unwanted effects early. The medication should never be combined with leflunomide, a related drug, due to the increased risk of serious side effects.
In summary, Aubagio is contraindicated during pregnancy due to its high risk of causing birth defects and other serious health complications. Both women and men must take strict precautions to avoid pregnancy while on this medication and for an extended period after stopping it. If pregnancy occurs, immediate consultation with a healthcare provider is essential to manage the risks to the unborn child and the mother’s health.
